Methods for regenerating poisoned salt bath comprising providing a salt bath comprising at least one of KNO.sub.3 and NaNO.sub.3, providing an ion-exchangeable substrate comprising lithium cations, contacting at least a portion of the ion-exchangeable substrate with the salt bath, whereby lithium cations in the salt bath diffuse from the ion-exchangeable substrate and are dissolved in the salt bath, and selectively precipitating dissolved lithium cations from the salt bath using phosphate salt. The methods further include preventing or reducing the formation of surface defects in the ion-exchangeable substrate by preventing or reducing the formation of crystals on the surface of the ion-exchangeable substrate upon removal from the salt bath.

The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.

The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.

The present invention relates to A process for the production of a molding, comprising (I) providing a zeolitic material; (II) mixing the zeolitic material provided in step (I) with one or more binders; (III) kneading of the mixture obtained in step (II); (IV) molding of the kneaded mixture obtained in step (III) to obtain one or more moldings; (V) drying of the one or more moldings obtained in step (IV); and (VI) calcining of the dried molding obtained in step (V); wherein the zeolitic material provided in step (I) displays a water adsorption ranging from 1 to 15 wt.-% when exposed to a relative humidity of 85%, as well as to a molding obtainable or obtained according to the inventive process in addition to a molding per se and to their respective use.

The present invention relates to A process for the production of a molding, comprising (I) providing a zeolitic material; (II) mixing the zeolitic material provided in step (I) with one or more binders; (III) kneading of the mixture obtained in step (II); (IV) molding of the kneaded mixture obtained in step (III) to obtain one or more moldings; (V) drying of the one or more moldings obtained in step (IV); and (VI) calcining of the dried molding obtained in step (V); wherein the zeolitic material provided in step (I) displays a water adsorption ranging from 1 to 15 wt.-% when exposed to a relative humidity of 85%, as well as to a molding obtainable or obtained according to the inventive process in addition to a molding per se and to their respective use.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

In an embodiment, the present disclosure pertains to a composition comprising a zeolite with high silica content. In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is 2:1. In some embodiments, the zeolite comprises Zeolite HOU-2 (LTA-type). In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is >3. In some embodiments, the zeolite comprises Zeolite HOU-3 (FAU type). In some embodiments, the zeolite is synthesized using a one-step method. In some embodiments, the zeolite is synthesized without the use of an organic structure-directing agent (OSDA). In some embodiments, the zeolite is synthesized without the use of post-synthesis dealumination. In some embodiments, the zeolite is synthesized without the use crystal seeds. In some embodiments, the zeolite is used in commercial ion exchange. In some embodiments, the zeolite is used for catalysis reaction. In some embodiments, the zeolite is highly thermostable.

In an embodiment, the present disclosure pertains to a composition comprising a zeolite with high silica content. In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is 2:1. In some embodiments, the zeolite comprises Zeolite HOU-2 (LTA-type). In some embodiments, the silica to aluminum ratio (SAR) for the zeolite is >3. In some embodiments, the zeolite comprises Zeolite HOU-3 (FAU type). In some embodiments, the zeolite is synthesized using a one-step method. In some embodiments, the zeolite is synthesized without the use of an organic structure-directing agent (OSDA). In some embodiments, the zeolite is synthesized without the use of post-synthesis dealumination. In some embodiments, the zeolite is synthesized without the use crystal seeds. In some embodiments, the zeolite is used in commercial ion exchange. In some embodiments, the zeolite is used for catalysis reaction. In some embodiments, the zeolite is highly thermostable.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.